Contractor Information. LCD Information. Local Coverage Determination (LCD): Ophthalmic Angiography (Fluorescein and Indocyanine Green) (L34426)

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Contractor Information. LCD Information. Local Coverage Determination (LCD): Ophthalmic Angiography (Fluorescein and Indocyanine Green) (L34426)"

Transcription

1 Local Coverage Determination (LCD): Ophthalmic Angiography (Fluorescein and Indocyanine Green) (L34426) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor Name Contract Type Contract Number Jurisdiction State(s) Palmetto GBA A and B MAC MAC A J - J Alabama Palmetto GBA A and B MAC MAC A J - J Georgia Palmetto GBA A and B MAC MAC A J - J Tennessee Palmetto GBA A and B and HHH MAC MAC A J - M South Carolina Palmetto GBA A and B and HHH MAC MAC B J - M South Carolina Palmetto GBA A and B and HHH MAC MAC A J - M Virginia Palmetto GBA A and B and HHH MAC MAC B J - M Virginia Palmetto GBA A and B and HHH MAC MAC A J - M West Virginia Palmetto GBA A and B and HHH MAC MAC B J - M West Virginia Palmetto GBA A and B and HHH MAC MAC A J - M North Carolina Palmetto GBA A and B and HHH MAC MAC B J - M North Carolina Back to Top LCD Information Document Information LCD ID L34426 Original ICD-9 LCD ID L31557 LCD Title Ophthalmic Angiography (Fluorescein and Indocyanine Green) Proposed LCD in Comment Period N/A Source Proposed LCD N/A AMA CPT / ADA CDT / AHA NUBC Copyright Statement Original Effective Date For services performed on or after 10/01/2015 Revision Effective Date For services performed on or after 01/29/2018 Revision Ending Date 02/25/2018 Retirement Date N/A Notice Period Start Date 09/08/2016 Notice Period End Date 10/23/2016 Printed on 1/29/2018. Page 1 of 24

2 CPT only copyright American Medical Association. All Rights Reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. The Code on Dental Procedures and Nomenclature (Code) is published in Current Dental Terminology (CDT). Copyright American Dental Association. All rights reserved. CDT and CDT-2016 are trademarks of the American Dental Association. UB-04 Manual. OFFICIAL UB-04 DATA SPECIFICATIONS MANUAL, 2014, is copyrighted by American Hospital Association ( AHA ), Chicago, Illinois. No portion of OFFICIAL UB-04 MANUAL may be reproduced, sorted in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior express, written consent of AHA. Health Forum reserves the right to change the copyright notice from time to time upon written notice to Company. CMS National Coverage Policy Title XVIII of the Social Security Act, 1862 (a)(1)(a) allows coverage and payment for only those services that are considered to be reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member. Title XVIII of the Social Security Act, 1862 (a)(14) defines other than physician services. Title XVIII of the Social Security Act, 1862 (a)(7) excludes routine physical examinations. Title XVIII of the Social Security Act, 1833 (e) prohibits Medicare payment for any claim which lacks the necessary information to process the claim. 42 CFR (a) indicates that diagnostic tests may only be ordered by the treating physician (or other treating practitioner acting within the scope of his or her license and Medicare requirements). 42 CFR defines physician assistants' services. 42 CFR defines nurse practitioners' services. 42 CFR defines clinical nurse specialists' services. CMS Internet-Only Manual, Pub , Medicare National Coverage Determinations Manual, Chapter 1, Part 1, 80.2, , 80.3 & Coverage Guidance Coverage Indications, Limitations, and/or Medical Necessity Abstract: Fluorescein Fluorescein angiography is used in the diagnosis and treatment of a wide range of ocular disorders. Its visible fluorescence leaking from damaged vessels makes it particularly useful in the diagnosis of retinal vascular disorders and monitoring treatment of conditions amenable to laser photocoagulation. Printed on 1/29/2018. Page 2 of 24

3 The dye is injected intravenously and serial photographs are taken through the pupil. While morphological characteristics alone may be pathognomonic of certain disease states, the timing of appearance of the dye in the choroid, in the central retinal artery and in the filling (or otherwise) of the quadrants have diagnostic implications. Indocyanine Green Indocyanine green dye is injected intravenously into the patient to highlight the vessels in the retina and the deeper tissue layer of the choroid. Under infrared light, Indocyanine Green fluoresces allowing the choroidal vessels to be visualized through the retinal pigment epithelium or in the presence of retinal or vitreous hemorrhage that would otherwise obscure visualization. Indocyanine green angiography (ICG) is effective in the diagnosis and treatment of ill-defined choroidal neovascularization (e.g., associated with age related macular degeneration (AMD)). It is also useful in the evalution of feeder vessels, choroidal leakages in the late phase, and ruptures of the pigment epithelium. Indications: Fluorescein Fluorescein angiography with interpretation is medically necessary as an adjunct to the diagnosis of chorioretinal vascular abnormalities especially relating to choroid neovascularization, noninfective vasculitis, and age related macular degeneration. It may also be appropriate in evaluating intraocular tumors, visual loss in systemic disease, acute exudative inflammations such as toxoplasmosis and optic disc edema. Medical necessity for such angiography would generally be in the context of a changing clinical picture. Fluorescein angiography may be useful in diabetic retinopathy in identifying ischemia and neovascularization, locating microaneurysms, and defining macular edema. Fluorescein angiography following treatment, for example, of choroidal neovascularization (CNV) is necessary to monitor for recurrence or to detect additional treatable disease. Usually this is performed on the basis of a change in the clinical picture similar to the way it is employed prior to treatment. However, fluorescein angiography may be performed following treatment without clinical change in order to detect occult lesions. This will occur most often in CNV and very rarely in other diseases. Indocyanine Green Indocyanine green angiography (ICG) may be a valuable diagnostic adjunct to fluorescein angiography in the evaluation of the following conditions: Retinal neovascularization Choroid neovascularization Serous detachment of retinal pigment epithelium Hemorrhagic detachment of retinal pigment epithelium Retinal hemorrhage Limitations: Fluorescein Studies performed for screening will be denied by Medicare as not medically necessary. Fluorescein angiography must be performed under the direct supervision (physician present in the office and immediately available) of a physician when done by a non-physician practitioner. If excluded by State law, optometrists may not be reimbursed for fluorescein angiography. Fluorescein angiography of an asymptomatic contralateral without new abnormalities on ophthalmoscopic exam, in patients with unilateral AMD or other disease, will be denied as not medically necessary. Evidence of medical necessity must be documented in the medical record for each. Indocyanine Green Indocyanine green angiography must be performed under the direct supervision (physician present in the office and immediately available) of a physician when done by a non-physician practitioner. Printed on 1/29/2018. Page 3 of 24

4 If excluded by State law, optometrists may not be reimbursed for ICG angiography. Indocyanine green is formulated with iodine and should not be used on patients who are allergic to iodine. ICG for the evaluation of patients with background diabetic retinopathy is not considered to be a medically necessary service. ICG angiography of an asymptomatic contralateral without new abnormalities on ophthalmoscopic exam, in patients with unilateral AMD or other disease, will be denied as not medically necessary. Evidence of medical necessity must be documented in the medical record for each. Studies performed for screening will be denied by Medicare as not medically necessary. Other Comments: Limitation of liability and refund requirements apply when denials are based on medical necessity. The provider/supplier must notify the beneficiary in writing, prior to rendering the service, if the provider/supplier is aware that the test, item or procedure may not be considered medically necessary by Medicare. The limitation of liability and refund requirements do not apply when the test, item or procedure is statutorily excluded, has no Medicare benefit category or is rendered for screening purposes. For outpatient settings other than CORFs, references to "physicians" throughout this policy include nonphysicians, such as nurse practitioners, clinical nurse specialists and physician assistants. Such non-physician practitioners, with certain exceptions, may certify, order and establish the plan of care as authorized by State law. (See Section CMS National Coverage Policy). Summary of Evidence N/A Analysis of Evidence (Rationale for Determination) N/A Back to Top Coding Information Bill Type Codes: Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the policy does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the policy should be assumed to apply equally to all claims. N/A Revenue Codes: Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the policy, services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the policy should be assumed to apply equally to all Revenue Codes. Printed on 1/29/2018. Page 4 of 24

5 N/A CPT/HCPCS Codes Group 1 Paragraph: CPT Code can only be billed with a single diagnosis if that diagnosis is a covered diagnosis for both CPT Code and CPT Code If the diagnosis to be billed for CPT is only a covered diagnosis for one of the two procedures encompassed in CPT 92242, the provider also needs to include a second diagnosis code on the claim that is a covered diagnosis for the other of the two studies in order to indicate that there exists a covered diagnosis for both studies included in CPT Group 1 Codes: FLUORESCEIN ANGIOGRAPHY (INCLUDES MULTIFRAME IMAGING) WITH INTERPRETATION AND REPORT, UNILATERAL OR BILATERAL INDOCYANINE-GREEN ANGIOGRAPHY (INCLUDES MULTIFRAME IMAGING) WITH INTERPRETATION AND REPORT, UNILATERAL OR BILATERAL FLUORESCEIN ANGIOGRAPHY AND INDOCYANINE-GREEN ANGIOGRAPHY (INCLUDES MULTIFRAME IMAGING) PERFORMED AT THE SAME PATIENT ENCOUNTER WITH INTERPRETATION AND REPORT, UNILATERAL OR BILATERAL ICD-10 Codes that Support Medical Necessity Group 1 Paragraph: The correct use of an ICD-10 code listed below does not assure coverage of a service. The service must be reasonable and necessary in the specific case and must meet the criteria specified in this determination. ICD-10 Codes for Fluorescein Angiography (92235) Group 1 Codes: ICD-10 Codes A18.53 Tuberculous chorioretinitis B20 Human immunodeficiency virus [HIV] disease B39.4 Histoplasmosis capsulati, unspecified B39.5 Histoplasmosis duboisii B39.9 Histoplasmosis, unspecified B58.01 Toxoplasma chorioretinitis C69.20 Malignant neoplasm of unspecified retina C69.21 Malignant neoplasm of right retina C69.22 Malignant neoplasm of left retina C69.30 Malignant neoplasm of unspecified choroid C69.31 Malignant neoplasm of right choroid C69.32 Malignant neoplasm of left choroid D18.09 Hemangioma of other sites D31.20 Benign neoplasm of unspecified retina D31.21 Benign neoplasm of right retina D31.22 Benign neoplasm of left retina D31.30 Benign neoplasm of unspecified choroid D31.31 Benign neoplasm of right choroid D31.32 Benign neoplasm of left choroid D57.00 Hb-SS disease with crisis, unspecified D57.01 Hb-SS disease with acute chest syndrome D57.02 Hb-SS disease with splenic sequestration D57.1 Sickle-cell disease without crisis D57.20 Sickle-cell/Hb-C disease without crisis D Sickle-cell/Hb-C disease with acute chest syndrome D Sickle-cell/Hb-C disease with splenic sequestration D Sickle-cell/Hb-C disease with crisis, unspecified D57.80 Other sickle-cell disorders without crisis Printed on 1/29/2018. Page 5 of 24

6 ICD-10 Codes D Other sickle-cell disorders with acute chest syndrome D Other sickle-cell disorders with splenic sequestration D Other sickle-cell disorders with crisis, unspecified D86.0 Sarcoidosis of lung D86.1 Sarcoidosis of lymph nodes D86.2 Sarcoidosis of lung with sarcoidosis of lymph nodes D86.3 Sarcoidosis of skin D86.81 Sarcoid meningitis D86.82 Multiple cranial nerve palsies in sarcoidosis D86.83 Sarcoid iridocyclitis D86.84 Sarcoid pyelonephritis D86.85 Sarcoid myocarditis D86.86 Sarcoid arthropathy D86.87 Sarcoid myositis D86.89 Sarcoidosis of other sites D86.9 Sarcoidosis, unspecified E Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right E Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left E Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, E Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right E Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left E Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, E Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right E Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left E Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, E Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right E Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left E Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, E Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right E Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left E Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, E Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right E Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left E Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right Printed on 1/29/2018. Page 6 of 24

7 ICD-10 Codes E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, E Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right E Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left E Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, E08.36 Diabetes mellitus due to underlying condition with diabetic cataract E08.37X1 Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right E08.37X2 Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left E08.37X3 Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, E08.39 Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication E Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right E Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left E Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, E Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right E Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left E Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, E Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right E Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left E Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, E Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right E Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left E Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, E Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right Printed on 1/29/2018. Page 7 of 24

8 ICD-10 Codes E Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left E Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, E Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right E Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left E Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, E Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right E Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left E Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, E09.36 Drug or chemical induced diabetes mellitus with diabetic cataract E09.37X1 Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right E09.37X2 Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left E09.37X3 Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, E09.39 Drug or chemical induced diabetes mellitus with other diabetic ophthalmic complication E Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right E Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left E Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, E Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right E Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left E Printed on 1/29/2018. Page 8 of 24

9 ICD-10 Codes Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, E Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right E Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left E Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, E Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right E Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left E Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, E Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right E Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left E Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, E Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right E Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left E Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, E Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right E Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left E Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, E Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right E Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left E Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, E Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right E Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left E Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, E Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right E Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left E Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, E Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right E Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left E Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, E Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right E Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left E Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, E Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified E10.37X1 Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right E10.37X2 Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left E10.37X3 Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, E10.39 Type 1 diabetes mellitus with other diabetic ophthalmic complication E Printed on 1/29/2018. Page 9 of 24

10 ICD-10 Codes Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right E Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left E Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, E Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right E Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left E Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, E Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right E Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left E Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, E Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right E Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left E Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, E Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right E Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left E Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, E Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right E Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left E Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, E Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right E Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left E Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, E Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right E Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left E Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, E Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right E Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left E Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, E Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right E Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left E Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, E Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right E Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left E Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, E Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right E Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left Printed on 1/29/2018. Page 10 of 24

11 ICD-10 Codes E Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, E11.36 Type 2 diabetes mellitus with diabetic cataract E11.37X1 Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right E11.37X2 Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left E11.37X3 Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, E11.39 Type 2 diabetes mellitus with other diabetic ophthalmic complication E Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right E Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left E Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, E Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right E Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left E Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, E Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right E Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left E Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, E Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right E Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left E Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, E Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right E Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left E Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, E Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right E Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left E Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, E Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right E Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left E Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, E Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right E Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left E Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, E Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right E Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left E Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, E Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right Printed on 1/29/2018. Page 11 of 24

12 ICD-10 Codes E Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left E Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, E Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right E Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left E Other specified diabetes mellitus with stable proliferative diabetic retinopathy, E Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right E Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left E Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, E13.36 Other specified diabetes mellitus with diabetic cataract E13.37X1 Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, right E13.37X2 Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, left E13.37X3 Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, E13.39 Other specified diabetes mellitus with other diabetic ophthalmic complication E78.00 Pure hypercholesterolemia, unspecified E78.01 Familial hypercholesterolemia E Postprocedural hematoma of an endocrine system organ or structure following an endocrine system procedure E Postprocedural hematoma of an endocrine system organ or structure following other procedure E Postprocedural seroma of an endocrine system organ or structure following an endocrine system procedure E Postprocedural seroma of an endocrine system organ or structure following other procedure G35 Multiple sclerosis G45.3 Amaurosis fugax G93.2 Benign intracranial hypertension H Unspecified focal chorioretinal inflammation, right H Unspecified focal chorioretinal inflammation, left H Unspecified focal chorioretinal inflammation, H Focal chorioretinal inflammation, juxtapapillary, right H Focal chorioretinal inflammation, juxtapapillary, left H Focal chorioretinal inflammation, juxtapapillary, H Focal chorioretinal inflammation of posterior pole, right H Focal chorioretinal inflammation of posterior pole, left H Focal chorioretinal inflammation of posterior pole, H Focal chorioretinal inflammation, peripheral, right H Focal chorioretinal inflammation, peripheral, left H Focal chorioretinal inflammation, peripheral, H Focal chorioretinal inflammation, macular or paramacular, right H Focal chorioretinal inflammation, macular or paramacular, left H Focal chorioretinal inflammation, macular or paramacular, H Unspecified disseminated chorioretinal inflammation, right H Unspecified disseminated chorioretinal inflammation, left H Unspecified disseminated chorioretinal inflammation, H Disseminated chorioretinal inflammation of posterior pole, right H Disseminated chorioretinal inflammation of posterior pole, left H Disseminated chorioretinal inflammation of posterior pole, H Disseminated chorioretinal inflammation, peripheral right H Disseminated chorioretinal inflammation, peripheral, left H Disseminated chorioretinal inflammation, peripheral, H Disseminated chorioretinal inflammation, generalized, right H Disseminated chorioretinal inflammation, generalized, left H Disseminated chorioretinal inflammation, generalized, Printed on 1/29/2018. Page 12 of 24

13 ICD-10 Codes H Acute posterior multifocal placoid pigment epitheliopathy, right H Acute posterior multifocal placoid pigment epitheliopathy, left H Acute posterior multifocal placoid pigment epitheliopathy, H30.21 Posterior cyclitis, right H30.22 Posterior cyclitis, left H30.23 Posterior cyclitis, H Harada's disease, right H Harada's disease, left H Harada's disease, H Other chorioretinal inflammations, right H Other chorioretinal inflammations, left H Other chorioretinal inflammations, H30.91 Unspecified chorioretinal inflammation, right H30.92 Unspecified chorioretinal inflammation, left H30.93 Unspecified chorioretinal inflammation, H Solar retinopathy, right H Solar retinopathy, left H Solar retinopathy, H Choroidal degeneration, unspecified, right H Choroidal degeneration, unspecified, left H Choroidal degeneration, unspecified, H Age-related choroidal atrophy, right H Age-related choroidal atrophy, left H Age-related choroidal atrophy, H Diffuse secondary atrophy of choroid, right H Diffuse secondary atrophy of choroid, left H Diffuse secondary atrophy of choroid, H31.21 Choroideremia H31.29 Other hereditary choroidal dystrophy H Choroidal rupture, right H Choroidal rupture, left H Choroidal rupture, H Hemorrhagic choroidal detachment, right H Hemorrhagic choroidal detachment, left H Hemorrhagic choroidal detachment, H Serous choroidal detachment, right H Serous choroidal detachment, left H Serous choroidal detachment, H32 Chorioretinal disorders in diseases classified elsewhere H Unspecified retinoschisis, right H Unspecified retinoschisis, left H Unspecified retinoschisis, H Cyst of ora serrata, right H Cyst of ora serrata, left H Cyst of ora serrata, H Other retinoschisis and retinal cysts, right H Other retinoschisis and retinal cysts, left H Other retinoschisis and retinal cysts, H33.21 Serous retinal detachment, right H33.22 Serous retinal detachment, left H33.23 Serous retinal detachment, H34.01 Transient retinal artery occlusion, right H34.02 Transient retinal artery occlusion, left H34.03 Transient retinal artery occlusion, H34.11 Central retinal artery occlusion, right H34.12 Central retinal artery occlusion, left H34.13 Central retinal artery occlusion, H Retinal artery branch occlusion, right Printed on 1/29/2018. Page 13 of 24

14 ICD-10 Codes H Retinal artery branch occlusion, left H Retinal artery branch occlusion, H Central retinal vein occlusion, right, with macular edema H Central retinal vein occlusion, right, with retinal neovascularization H Central retinal vein occlusion, right, stable H Central retinal vein occlusion, left, with macular edema H Central retinal vein occlusion, left, with retinal neovascularization H Central retinal vein occlusion, left, stable H Central retinal vein occlusion,, with macular edema H Central retinal vein occlusion,, with retinal neovascularization H Central retinal vein occlusion,, stable H Venous engorgement, right H Venous engorgement, left H Venous engorgement, H Tributary (branch) retinal vein occlusion, right, with macular edema H Tributary (branch) retinal vein occlusion, right, with retinal neovascularization H Tributary (branch) retinal vein occlusion, right, stable H Tributary (branch) retinal vein occlusion, left, with macular edema H Tributary (branch) retinal vein occlusion, left, with retinal neovascularization H Tributary (branch) retinal vein occlusion, left, stable H Tributary (branch) retinal vein occlusion,, with macular edema H Tributary (branch) retinal vein occlusion,, with retinal neovascularization H Tributary (branch) retinal vein occlusion,, stable H34.9 Unspecified retinal vascular occlusion H Exudative retinopathy, right H Exudative retinopathy, left H Exudative retinopathy, H Hypertensive retinopathy, right H Hypertensive retinopathy, left H Hypertensive retinopathy, H Retinal micro-aneurysms, unspecified, right H Retinal micro-aneurysms, unspecified, left H Retinal micro-aneurysms, unspecified, H Retinal neovascularization, unspecified, right H Retinal neovascularization, unspecified, left H Retinal neovascularization, unspecified, H Retinal vasculitis, right H Retinal vasculitis, left H Retinal vasculitis, H Retinal telangiectasis, right H Retinal telangiectasis, left H Retinal telangiectasis, H35.09 Other intraretinal microvascular abnormalities H35.21 Other non-diabetic proliferative retinopathy, right H35.22 Other non-diabetic proliferative retinopathy, left H35.23 Other non-diabetic proliferative retinopathy, H Nonexudative age-related macular degeneration, right, early dry stage H Nonexudative age-related macular degeneration, right, intermediate dry stage H Nonexudative age-related macular degeneration, right, advanced atrophic without subfoveal involvement H Nonexudative age-related macular degeneration, right, advanced atrophic with subfoveal involvement H Nonexudative age-related macular degeneration, left, early dry stage H Nonexudative age-related macular degeneration, left, intermediate dry stage H Nonexudative age-related macular degeneration, left, advanced atrophic without subfoveal involvement H Nonexudative age-related macular degeneration, left, advanced atrophic with subfoveal involvement Printed on 1/29/2018. Page 14 of 24

15 ICD-10 Codes H Nonexudative age-related macular degeneration,, early dry stage H Nonexudative age-related macular degeneration,, intermediate dry stage H Nonexudative age-related macular degeneration,, advanced atrophic without subfoveal involvement H Nonexudative age-related macular degeneration,, advanced atrophic with subfoveal involvement H Exudative age-related macular degeneration, right, with active choroidal neovascularization H Exudative age-related macular degeneration, right, with inactive choroidal neovascularization H Exudative age-related macular degeneration, right, with inactive scar H Exudative age-related macular degeneration, left, with active choroidal neovascularization H Exudative age-related macular degeneration, left, with inactive choroidal neovascularization H Exudative age-related macular degeneration, left, with inactive scar H Exudative age-related macular degeneration,, with active choroidal neovascularization H Exudative age-related macular degeneration,, with inactive choroidal neovascularization H Exudative age-related macular degeneration,, with inactive scar H35.33 Angioid streaks of macula H Macular cyst, hole, or pseudohole, right H Macular cyst, hole, or pseudohole, left H Macular cyst, hole, or pseudohole, H Cystoid macular degeneration, right H Cystoid macular degeneration, left H Cystoid macular degeneration, H Drusen (degenerative) of macula, right H Drusen (degenerative) of macula, left H Drusen (degenerative) of macula, H Puckering of macula, right H Puckering of macula, left H Puckering of macula, H Toxic maculopathy, right H Toxic maculopathy, left H Toxic maculopathy, H35.52 Pigmentary retinal dystrophy H35.53 Other dystrophies primarily involving the sensory retina H35.54 Dystrophies primarily involving the retinal pigment epithelium H35.61 Retinal hemorrhage, right H35.62 Retinal hemorrhage, left H35.63 Retinal hemorrhage, H Central serous chorioretinopathy, right H Central serous chorioretinopathy, left H Central serous chorioretinopathy, H Serous detachment of retinal pigment epithelium, right H Serous detachment of retinal pigment epithelium, left H Serous detachment of retinal pigment epithelium, H Hemorrhagic detachment of retinal pigment epithelium, right H Hemorrhagic detachment of retinal pigment epithelium, left H Hemorrhagic detachment of retinal pigment epithelium, H35.81 Retinal edema H35.82 Retinal ischemia H43.11 Vitreous hemorrhage, right H43.12 Vitreous hemorrhage, left H43.13 Vitreous hemorrhage, H Vitreomacular adhesion, right H Vitreomacular adhesion, left H Vitreomacular adhesion, H43.89 Other disorders of vitreous body H43.9 Unspecified disorder of vitreous body H44.21 Degenerative myopia, right H44.22 Degenerative myopia, left Printed on 1/29/2018. Page 15 of 24

16 ICD-10 Codes H44.23 Degenerative myopia, H44.2A1 Degenerative myopia with choroidal neovascularization, right H44.2A2 Degenerative myopia with choroidal neovascularization, left H44.2A3 Degenerative myopia with choroidal neovascularization, H44.2B1 Degenerative myopia with macular hole, right H44.2B2 Degenerative myopia with macular hole, left H44.2B3 Degenerative myopia with macular hole, H44.2E1 Degenerative myopia with other maculopathy, right H44.2E2 Degenerative myopia with other maculopathy, left H44.2E3 Degenerative myopia with other maculopathy, H46.01 Optic papillitis, right H46.02 Optic papillitis, left H46.03 Optic papillitis, H Ischemic optic neuropathy, right H Ischemic optic neuropathy, left H Ischemic optic neuropathy, H47.10 Unspecified papilledema H Drusen of optic disc, right H Drusen of optic disc, left H Drusen of optic disc, H Pseudopapilledema of optic disc, right H Pseudopapilledema of optic disc, left H Pseudopapilledema of optic disc, H Other disorders of optic disc, right H Other disorders of optic disc, left H Other disorders of optic disc, H Cystoid macular edema following cataract surgery, right H Cystoid macular edema following cataract surgery, left H Cystoid macular edema following cataract surgery, M06.9 Rheumatoid arthritis, unspecified Q14.8 Other congenital malformations of posterior segment of Z Other long term (current) drug therapy Group 2 Paragraph: ICD-10 Codes For Indocyanine Green Angiography (92240) Group 2 Codes: ICD-10 Codes A18.53 Tuberculous chorioretinitis D31.31 Benign neoplasm of right choroid D31.32 Benign neoplasm of left choroid H Unspecified disseminated chorioretinal inflammation, right H Unspecified disseminated chorioretinal inflammation, left H Unspecified disseminated chorioretinal inflammation, H Disseminated chorioretinal inflammation of posterior pole, right H Disseminated chorioretinal inflammation of posterior pole, left H Disseminated chorioretinal inflammation of posterior pole, H Disseminated chorioretinal inflammation, peripheral right H Disseminated chorioretinal inflammation, peripheral, left H Disseminated chorioretinal inflammation, peripheral, H Disseminated chorioretinal inflammation, generalized, right H Disseminated chorioretinal inflammation, generalized, left H Disseminated chorioretinal inflammation, generalized, H31.8 Other specified disorders of choroid Printed on 1/29/2018. Page 16 of 24

Contractor Information. LCD Information. Local Coverage Determination (LCD): Ophthalmic Angiography (Fluorescein and Indocyanine Green) (L34426)

Contractor Information. LCD Information. Local Coverage Determination (LCD): Ophthalmic Angiography (Fluorescein and Indocyanine Green) (L34426) Local Coverage Determination (LCD): Ophthalmic Angiography (Fluorescein and Indocyanine Green) (L34426) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

More information

Local Coverage Determination (LCD): RAST Type Tests ( L30524 )

Local Coverage Determination (LCD): RAST Type Tests ( L30524 ) Page 2 of 6 Local Coverage Determination (LCD): RAST Type Tests ( L30524 ) Contractor Information Contractor Name Novitas Solutions, Inc. Contract Number 12502 Contract Type A and B MAC LCD Information

More information

ICD-10-CM Are You Prepared? Part IV Posterior Segment

ICD-10-CM Are You Prepared? Part IV Posterior Segment ICD-10-CM Are You Prepared? Part IV Posterior Segment Rebecca H. Wartman OD April 2014 With contributions from Doug Morrow OD & Harvey Richman OD Overview This webinar will provide an introduction to ICD-10-CM

More information

Contractor Number Oversight Region Region IV

Contractor Number Oversight Region Region IV Local Coverage Determination (LCD) for Hospice - Renal Care (L31538) Contractor Information Contractor Name Palmetto GBA opens in new window Contractor Number 11004 Contractor Type HHH MAC LCD Information

More information

MolDX: HLA-DQB1*06:02 Testing for Narcolepsy

MolDX: HLA-DQB1*06:02 Testing for Narcolepsy MolDX: HLA-DQB1*06:02 Testing for Narcolepsy CGS Administrators, LLC Jump to Section... Please Note: This is a Proposed LCD. Proposed LCDs are works in progress and not necessarily a reflection of the

More information

Ophthalmologic Policy. Vascular Endothelial Growth Factor (VEGF) Inhibitors

Ophthalmologic Policy. Vascular Endothelial Growth Factor (VEGF) Inhibitors Ophthalmologic Policy UnitedHealthcare Commercial Drug Policy Vascular Endothelial Growth Factor (VEGF) Inhibitors Policy Number: 2016D0042H Effective Date: October 1, 2016 Table of Contents Page INSTRUCTIONS

More information

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Jurisdiction Texas. Retirement Date N/A

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Jurisdiction Texas. Retirement Date N/A Local Coverage Determination (LCD): Chiropractic Services (L35424) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor

More information

Contractor Information. LCD Information. FUTURE Local Coverage Determination (LCD): Trigger Point Injections (L35010) Document Information

Contractor Information. LCD Information. FUTURE Local Coverage Determination (LCD): Trigger Point Injections (L35010) Document Information FUTURE Local Coverage Determination (LCD): Trigger Point Injections (L35010) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Please note: Future Effective

More information

ICD-10-CM Are you Prepared? Disclaimers for Presentation. Disclaimers for Presentation 5/13/2014. What is ICD-10-CM/PCS

ICD-10-CM Are you Prepared? Disclaimers for Presentation. Disclaimers for Presentation 5/13/2014. What is ICD-10-CM/PCS AOA Third Party Center Coding Experts Are you Prepared? Rebecca H. Wartman O.D. Optometry s Meeting 2014 With contributions from Doug Morrow O.D. & Harvey Richman O.D. Rebecca H. Wartman, O.D Douglas C.

More information

Local Coverage Determination (LCD): Speech-Language Pathology (SLP) Services: Dysphagia; Includes VitalStim Therapy (L34891)

Local Coverage Determination (LCD): Speech-Language Pathology (SLP) Services: Dysphagia; Includes VitalStim Therapy (L34891) Local Coverage Determination (LCD): Speech-Language Pathology (SLP) Services: Dysphagia; Includes VitalStim Therapy (L34891) Links in PDF documents are not guaranteed to work. To follow a web link, please

More information

Clinical Policy: Implantable Miniature Telescope for Age Related Macular Degeneration Reference Number: CP.MP.517

Clinical Policy: Implantable Miniature Telescope for Age Related Macular Degeneration Reference Number: CP.MP.517 Clinical Policy: Implantable Miniature Telescope for Age Related Macular Reference Number: CP.MP.517 Effective Date: 11/16 Last Review Date: 11/17 See Important Reminder at the end of this policy for important

More information

Clinical Policy: Bevacizumab (Avastin) Reference Number: ERX.SPMN.127

Clinical Policy: Bevacizumab (Avastin) Reference Number: ERX.SPMN.127 Clinical Policy: (Avastin) Reference Number: ERX.SPMN.127 Effective Date: 03/14 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Retirement Date N/A

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Retirement Date N/A Local Coverage Determination (LCD): Bone Mass Measurement (L36460) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor

More information

PREAMBLE TO MSC PAYMENT SCHEDULE: OPTOMETRY SERVICES

PREAMBLE TO MSC PAYMENT SCHEDULE: OPTOMETRY SERVICES PREAMBLE TO MSC PAYMENT SCHEDULE: OPTOMETRY SERVICES A. GENERAL PROVISIONS 1. Eye Examination Benefits Optometric benefits are services defined in Section 23 of the Medical and Health Care Services Regulations,

More information

UVEITIS. Dr. Yılmaz ÖZYAZGAN

UVEITIS. Dr. Yılmaz ÖZYAZGAN UVEITIS Dr. Yılmaz ÖZYAZGAN UVEITIS DEFINITION BY STRICT DEFINITION, UVEITIS IS AN INFLAMMATION OF UVEAL TRACT. BUT IN PRACTICAL, IT IS GENERALLY NOT RESTRICTED TO THE UVEA AND INVOLVES OTHER ADJACENT

More information

Clinical Policy: Neovascular (WET) Macular Degeneration Treatment Reference Number: CP.MP.283

Clinical Policy: Neovascular (WET) Macular Degeneration Treatment Reference Number: CP.MP.283 Clinical Policy: Neovascular (WET) Macular Degeneration Treatment Reference Number: CP.MP.283 Effective Date: 11/16 Last Review Date: 11/17 See Important Reminder at the end of this policy for important

More information

Therapeutic Shoes for Diabetics

Therapeutic Shoes for Diabetics Last Review Date: August 11, 2017 Number: MG.MM.DM.03bC8v2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth

More information

Bevacizumab (Avastin)

Bevacizumab (Avastin) Bevacizumab (Avastin) Policy Number: Original Effective Date: MM.04.001 09/14/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 03/01/2014 Section: Prescription Drugs Place(s) of Service:

More information

Contractor Information. LCD Information. FUTURE Local Coverage Determination (LCD): Routine Foot Care (L35138) Document Information

Contractor Information. LCD Information. FUTURE Local Coverage Determination (LCD): Routine Foot Care (L35138) Document Information FUTURE Local Coverage Determination (LCD): Routine Foot Care (L35138) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Please note: Future Effective

More information

Ocular Pathology. I. Congenital and/or developmental. A. Trisomy 21. Hypertelorism (widely spaced eyes) Keratoconus (cone shaped cornea)

Ocular Pathology. I. Congenital and/or developmental. A. Trisomy 21. Hypertelorism (widely spaced eyes) Keratoconus (cone shaped cornea) I. Congenital and/or developmental Robbins Pathologic Basis of Disease, 6 th Ed. A. Trisomy 21 Hypertelorism (widely spaced eyes) Keratoconus (cone shaped cornea) Focal hypoplasia of iris Cataracts frequently

More information

ICD 10 CM OPHTHALMOLOGY 2017 Quick Reference Guide SYMPTOMS CATARACT/LENS. with status migrainosus... G43.801

ICD 10 CM OPHTHALMOLOGY 2017 Quick Reference Guide SYMPTOMS CATARACT/LENS. with status migrainosus... G43.801 ICD 10 CM OPHTHALMOLOGY 2017 Quick Reference Guide SYMPTOMS Blurred vision (368.8)... H53.8 Contusion of eyeball and orbital tissues (921.3) eye initial encounter... S05.11XA subsequent encounter... S05.11XD

More information

INFORMED CONSENT FOR AVASTIN TM (BEVACIZUMAB) INTRAVITREAL INJECTION

INFORMED CONSENT FOR AVASTIN TM (BEVACIZUMAB) INTRAVITREAL INJECTION INFORMED CONSENT FOR AVASTIN TM (BEVACIZUMAB) INTRAVITREAL INJECTION INDICATIONS: Age-related macular degeneration (AMD) is the leading cause of blindness in people over 50 years of age. It is caused by

More information

Local Coverage Determination (LCD) for Cardiac Catheterization (L29090)

Local Coverage Determination (LCD) for Cardiac Catheterization (L29090) Local Coverage Determination (LCD) for Cardiac Catheterization (L29090) Contractor Information Contractor Name First Coast Service Options, Inc. Contractor Number 09102 Contractor Type MAC - Part B LCD

More information

2017 Clinical Quality Measures

2017 Clinical Quality Measures 2017 Clinical Quality Measures Clinical quality measures, or CQMs, are statistics that seek to quantify the quality of services performed by health care providers. These statistics involve data related

More information

Experience Spectacular Retinal Imaging with the new NIDEK F-10 Digital Ophthalmoscope

Experience Spectacular Retinal Imaging with the new NIDEK F-10 Digital Ophthalmoscope Experience Spectacular Retinal Imaging with the new NIDEK F-10 Digital Ophthalmoscope The F-10 was developed to give Ophthalmologists a high definition (HD) diagnostic imaging system. Designed to provide

More information

Contractor Information. LCD Information. Local Coverage Determination (LCD): Magnetic Resonance Imaging of the Orbit, Face, and/or Neck (L34425)

Contractor Information. LCD Information. Local Coverage Determination (LCD): Magnetic Resonance Imaging of the Orbit, Face, and/or Neck (L34425) Local Coverage Determination (LCD): Magnetic Resonance Imaging of the Orbit, Face, and/or Neck (L34425) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

More information

Fundamentals of Retina Coding

Fundamentals of Retina Coding Fundamentals of Retina Coding Presented by: Joy Woodke, COE, OCS Sunday, April 2, 2017 ASRS Business of Retina Meeting Dallas, TX American Academy of Ophthalmic Executives Financial Disclosure Joy Woodke,

More information

Fundus Fluorescein Angiography in Diabetic Retinopathy: Correlation of Angiographic Findings to the Clinical Maculopathy Abstract: Purpose:

Fundus Fluorescein Angiography in Diabetic Retinopathy: Correlation of Angiographic Findings to the Clinical Maculopathy Abstract: Purpose: IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 15, Issue 2 Ver. XII (Feb. 2016), PP 80-88 www.iosrjournals.org Fundus Fluorescein Angiography in Diabetic

More information

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY Measure #192 (NQF 0564): Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures National Quality Strategy Domain: Patient Safety 2016 PQRS OPTIONS FOR

More information

White-Spot Syndromes of the Retina Lee Jampol, M.D. Chicago, IL

White-Spot Syndromes of the Retina Lee Jampol, M.D. Chicago, IL Objectives At the conclusion of the program, the attendees will be able to: 1. recognize the various white-spot syndromes of the retina 2. initiate appropriate diagnostic tests of patients with the white-spot

More information

2017 Reimbursement Information for Mammography, CAD and Digital Breast Tomosynthesis 1

2017 Reimbursement Information for Mammography, CAD and Digital Breast Tomosynthesis 1 GE Healthcare 2017 Reimbursement Information for Mammography, CAD and Digital Breast Tomosynthesis 1 February 2017 www.gehealthcare.com/reimbursement This advisory addresses Medicare coding, coverage and

More information

CNV can be divided into either classic or occult based on angiographic findings. Occult can be further subdivided into Type I or Type II.

CNV can be divided into either classic or occult based on angiographic findings. Occult can be further subdivided into Type I or Type II. T H E M E : E Y E PHOTODYNAMIC THERAPY FOR AGE-RELATED MACULAR DEGENERATION: A NEW TREATMENT OPTION Dr Yap Eng Kiat What is age-related macula degeneration (AMD)? It is a degenerative eye disease that

More information

Note: This is an outcome measure and will be calculated solely using registry data.

Note: This is an outcome measure and will be calculated solely using registry data. Measure #384: Adult Primary Rhegmatogenous Retinal Detachment Surgery: No Return to the Operating Room Within 90 Days of Surgery National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR

More information

West Los Angeles VA Health Care Center

West Los Angeles VA Health Care Center West Los Angeles VA Health Care Center A review of the demographics of a group of general optometry patients seen recently (2015) at the main eye clinic in bldg. 304 yielded the following: Age range: 33-75

More information

Coding Terminology Getting Back To The Basics. Financial Interest. Getting Back To The Basics. Rose & Associates

Coding Terminology Getting Back To The Basics. Financial Interest. Getting Back To The Basics. Rose & Associates Coding Terminology Getting Back To The Basics ASCRS ASOA Symposium & Congress Administrator Program Boston, Massachusetts April 25-29, 2014 Presented by: Patricia Kennedy, COMT, CPC, COE Financial Interest

More information

FUTURE DRAFT Local Coverage Determination for Chemodenervation (DL31701)

FUTURE DRAFT Local Coverage Determination for Chemodenervation (DL31701) FUTURE DRAFT Local Coverage Determination for Chemodenervation (DL31701) http://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?lcdid=32955&... Page 1 of 14 Search Home Medicare Medicaid

More information

Vi t rectomy and silicone oil tamponade for serous macular detachment associated with an optic disk pit

Vi t rectomy and silicone oil tamponade for serous macular detachment associated with an optic disk pit E u ropean Journal of Ophthalmology / Vol. 16 no. 2, 2006 / pp. 3 3 0-3 3 4 S H O RT COMMUNICAT I O N Vi t rectomy and silicone oil tamponade for serous macular detachment associated with an optic disk

More information

2015 Facility and Physician Billing Guide Heart Valve Technologies

2015 Facility and Physician Billing Guide Heart Valve Technologies 2015 Facility and Physician Billing Guide Heart Valve Technologies PHYSICIAN BILLING CODES Clinicians use Current Procedural Terminology (CPT 1 ) codes to bill for procedures and services. Each CPT code

More information

Study of clinical significance of optical coherence tomography in diagnosis & management of diabetic macular edema

Study of clinical significance of optical coherence tomography in diagnosis & management of diabetic macular edema Original Research Article Study of clinical significance of optical coherence tomography in diagnosis & management of diabetic macular edema Neha Kantilal Desai 1,*, Somesh Vedprakash Aggarwal 2, Sonali

More information

FLORIDA MEDICARE PART B LOCAL MEDICAL REVIEW POLICY

FLORIDA MEDICARE PART B LOCAL MEDICAL REVIEW POLICY FLORIDA MEDICARE PART B LOCAL MEDICAL REVIEW POLICY CPT/HCPCS Codes 93925 Duplex scan of lower extremity arteries or arterial bypass grafts; complete bilateral study 93926 unilateral or limited study Policy

More information

MedStar Health, Inc. POLICY AND PROCEDURE MANUAL

MedStar Health, Inc. POLICY AND PROCEDURE MANUAL MedStar Health, Inc. POLICY AND PROCEDURE MANUAL MP.049.MH Visually Evoked Response Test This policy applies to the following lines of business: MedStar Employee (Select) MedStar MA DSNP CSNP MedStar CareFirst

More information

Photodynamic Therapy (PDT) for agerelated

Photodynamic Therapy (PDT) for agerelated Page 1 of 5 Photodynamic Therapy (PDT) for agerelated eye conditions Introduction This leaflet gives you information about Photodynamic Therapy (PDT) for the age--related eye conditions macular degeneration

More information

Vascular Plug Procedures 2014 CODING AND PAYMENT REFERENCE GUIDE ST. JUDE MEDICAL - CARDIOVASCULAR DIVISION

Vascular Plug Procedures 2014 CODING AND PAYMENT REFERENCE GUIDE ST. JUDE MEDICAL - CARDIOVASCULAR DIVISION Vascular Plug Procedures 2014 CODING AND PAYMENT REFERENCE GUIDE ST. JUDE MEDICAL - CARDIOVASCULAR DIVISION IMPORTANT: St. Jude Medical provides this reference guide for general information purposes only

More information

Clinical Policy: Bevacizumab (Avastin) Reference Number: CP.PHAR.93

Clinical Policy: Bevacizumab (Avastin) Reference Number: CP.PHAR.93 Clinical Policy: (Avastin) Reference Number: CP.PHAR.93 Effective Date: 12/11 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS

VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS FOR OPHTHALMIC USE Policy Number: 2016D0001B Effective Date: January 1, 2016 Table of Contents: Page: Cross Reference Policy: POLICY DESCRIPTION 2 ZALTRAP

More information

Jurisdiction Nebraska. Retirement Date N/A

Jurisdiction Nebraska. Retirement Date N/A If you wish to save the PDF, please ensure that you change the file extension to.pdf (from.ashx). Local Coverage Determination (LCD): BONE Mass Measurement (L31620) Contractor Information Contractor Name

More information

Retinal Imaging. Retinal Physiology

Retinal Imaging. Retinal Physiology Retinal Imaging The eyes are the window to the soul 16 th century proverb The retina gives an unobstructed view of the human vascular. Also, retinal imaging is important for diagnosing retina diseases.

More information

OCT imaging of choroidal neovascularisation and its role in the determination of patients eligibility for surgery

OCT imaging of choroidal neovascularisation and its role in the determination of patients eligibility for surgery 438 Br J Ophthalmol 1999;83:438 442 OCT imaging of choroidal neovascularisation and its role in the determination of patients eligibility for surgery A Giovannini, G P Amato, C Mariotti, B Scassellati-Sforzolini

More information

NEW YORK UNIVERSITY SCHOOL OF MEDICINE DEPARTMENT OF OPHTHALMOLOGY EDUCATIONAL OBJECTIVES AND GOALS

NEW YORK UNIVERSITY SCHOOL OF MEDICINE DEPARTMENT OF OPHTHALMOLOGY EDUCATIONAL OBJECTIVES AND GOALS NEW YORK UNIVERSITY SCHOOL OF MEDICINE DEPARTMENT OF OPHTHALMOLOGY EDUCATIONAL OBJECTIVES AND GOALS Revision Date: 6/30/06 Distribution Date: 7/6/06 The Department of Ophthalmology at the NYU Medical Center

More information

Prothrombin Time (PT)

Prothrombin Time (PT) Other Names/Abbreviations PT 190.17 - Prothrombin Time (PT) Basic plasma coagulation function is readily assessed with a few simple laboratory tests: the Partial Thromboplastin Time (PTT), Prothrombin

More information

Clinical Policy: Ambulatory Electroencephalography Reference Number: CP.MP.96

Clinical Policy: Ambulatory Electroencephalography Reference Number: CP.MP.96 Clinical Policy: Ambulatory Electroencephalography Reference Number: CP.MP.96 Effective Date: 09/15 Last Review Date: 09/17 See Important Reminder at the end of this policy for important regulatory and

More information

How can DIABETES affect my EYES? Dr Deborah M Broadbent Honorary Senior Lecturer Department of Eye and Vision Science University of Liverpool

How can DIABETES affect my EYES? Dr Deborah M Broadbent Honorary Senior Lecturer Department of Eye and Vision Science University of Liverpool How can DIABETES affect my EYES? By: Dr Deborah M Broadbent Honorary Senior Lecturer Department of Eye and Vision Science University of Liverpool HOW CAN DIABETES AFFECT MY EYES? What is diabetic retinopathy?

More information

MEDICAL POLICY: Telehealth Services

MEDICAL POLICY: Telehealth Services POLICY: PG0142 ORIGINAL EFFECTIVE: 01/01/08 LAST REVIEW: 12/12/17 MEDICAL POLICY: Telehealth Services GUIDELINES This policy does not certify benefits or authorization of benefits, which is designated

More information

Eye and Ocular Adnexa, Auditory Systems

Eye and Ocular Adnexa, Auditory Systems Eye and Ocular Adnexa, Auditory Systems CPT copyright 2011 American Medical Association. All rights reserved. Fee schedules, relative value units, conversion factors and/or related components are not assigned

More information

Posterior Segment. Interesting Image Symposium. Coloboma. Morning Glory 3/23/2016. Morning Glory. 1. Glaucoma. 2. Coloboma. 3.

Posterior Segment. Interesting Image Symposium. Coloboma. Morning Glory 3/23/2016. Morning Glory. 1. Glaucoma. 2. Coloboma. 3. Posterior Segment Interesting Image Symposium Morning Glory 1. Glaucoma 2. Coloboma 3. Morning Glory 4. Posterior Staphyloma Morning Glory Coloboma 1. Glaucoma 2. Coloboma 3. Morning Glory 4. Posterior

More information

Measure #117 (NQF 0055): Diabetes: Eye Exam National Quality Strategy Domain: Effective Clinical Care

Measure #117 (NQF 0055): Diabetes: Eye Exam National Quality Strategy Domain: Effective Clinical Care Measure #117 (NQF 0055): Diabetes: Eye Exam National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS F INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION: Percentage of patients 18-75

More information

Contractor Information. LCD Information. Local Coverage Determination (LCD): Cardiac Radionuclide Imaging (L33457) Document Information

Contractor Information. LCD Information. Local Coverage Determination (LCD): Cardiac Radionuclide Imaging (L33457) Document Information Local Coverage Determination (LCD): Cardiac Radionuclide Imaging (L33457) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Glaucoma, Evaluation by Ophthalmologic Techniques File Name: Origination: Last CAP Review: Next CAP Review: Last Review: glaucoma_evaluation_by_ophthalmologic_techniques 3/2001

More information

Age-related macular degeneration in Hong Kong Chinese angiographic features and outcomes

Age-related macular degeneration in Hong Kong Chinese angiographic features and outcomes ORIGINAL RESEARCH ORIGINAL RESEARCH Age-related macular degeneration in Hong Kong Chinese angiographic features and outcomes Patrick K. W. Wu, FRCS, Raymond C. W. Fu, FRCS, Clement W. N. Chan, FRCS, FHKAM(Ophth)

More information

Clinical Policy: Essure Removal Reference Number: CP.MP.131

Clinical Policy: Essure Removal Reference Number: CP.MP.131 Clinical Policy: Reference Number: CP.MP.131 Effective Date: 11/16 Last Review Date: 11/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

OP-8: MRI LUMBAR SPINE FOR LOW BACK PAIN

OP-8: MRI LUMBAR SPINE FOR LOW BACK PAIN Description of Measure OP-8: MRI LUMBAR SPINE FOR LOW BACK PAIN This measure calculates the percentage of MRI of the Lumbar Spine studies with a diagnosis of low back pain on the imaging claim and for

More information

Treatment of visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO):

Treatment of visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO): Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Treatment of visual impairment due to macular edema secondary to branch retinal

More information

OP-10: ABDOMEN CT USE OF CONTRAST MATERIAL

OP-10: ABDOMEN CT USE OF CONTRAST MATERIAL Description of Measure OP-10: ABDOMEN CT USE OF CONTRAST MATERIAL This measure calculates the percentage of abdomen studies that are performed with and without contrast out of all abdomen studies performed

More information

Retina. Chapter 4. The Eyes Have It. by Tim Root

Retina. Chapter 4. The Eyes Have It. by Tim Root Chapter 4 Retina The Eyes Have It There are certain rules of etiquette you should follow when performing PRP laser. For example, never say you re Killing, Burning, Zapping, or Liquidating the retina by

More information

Case Report Isolated Multiple Pigment Epithelial Detachments with Unknown Cause

Case Report Isolated Multiple Pigment Epithelial Detachments with Unknown Cause Case Reports in Ophthalmological Medicine, Article ID 289107, 4 pages http://dx.doi.org/10.1155/2014/289107 Case Report Isolated Multiple Pigment Epithelial Detachments with Unknown Cause Arzu Seyhan Karatepe

More information

Clinical Policy: Digital Breast Tomosynthesis Reference Number: CP.MP.90

Clinical Policy: Digital Breast Tomosynthesis Reference Number: CP.MP.90 Clinical Policy: Reference Number: CP.MP.90 Effective Date: 01/18 Last Review Date: 12/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

Diabetic Retinopathy

Diabetic Retinopathy Diabetic Retinopathy Overview This presentation covers the following topics: Definitions Epidemiology of diabetic retinopathy Evidence for public health approaches Screening for diabetic retinopathy Health

More information

Local Coverage Determination for Chiropractic Services (L28249)

Local Coverage Determination for Chiropractic Services (L28249) Page 1 of 11 Return to Previous Page Back to Local Coverage Determinations (LCDs) for Palmetto GBA (01192, MAC - Part B) Local Coverage Determination (LCD): Chiropractic Services (L28249) Select the Print

More information

International Classification of Diseases 9th Revision, Clinical Modification ICD-9-CM. Volumes 1 & 2

International Classification of Diseases 9th Revision, Clinical Modification ICD-9-CM. Volumes 1 & 2 International Classification of Diseases 9th Revision, Clinical Modification 2009 Physicians' Professional ICD-9-CM Volumes 1 & 2 Codes valid for use October 1, 2008 September 30, 2009 Table of Contents

More information

REIMBURSEMENT GUIDE. Sovereign. Spinal System

REIMBURSEMENT GUIDE. Sovereign. Spinal System REIMBURSEMENT GUIDE Sovereign Spinal System REIMBURSEMENT GUIDE The Sovereign Spinal System is indicated for use with autogenous bone graft in patients with degenerative disc disease The Sovereign Spinal

More information

Clinical Policy: Refractive Surgery Reference Number: CP.MP. 391

Clinical Policy: Refractive Surgery Reference Number: CP.MP. 391 Clinical Policy: Refractive Surgery Reference Number: CP.MP. 391 Effective Date: November 2007 Last Review Date: January 2016 Coding Implications Revision Log See Important Reminder at the end of this

More information

Intravenous Immune Globulin (IVIg)

Intravenous Immune Globulin (IVIg) Policy Number Reimbursement Policy IVIG04272010RP Approved By UnitedHealthcare Medicare Reimbursement Policy Committee Current Approval Date 10/08/2014 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This

More information

Local Coverage Determination (LCD) for Noninvasive Cerebrovascular Studies (L28283)

Local Coverage Determination (LCD) for Noninvasive Cerebrovascular Studies (L28283) Search Home Medicare Medicaid CHIP About CMS Regulations & Guidance Research, Statistics, Data & Systems Outreach & Education People with Medicare & Medicaid Questions Careers Newsroom Contact CMS Acronyms

More information

Case Report Inherent Challenges in Managing Long Standing Refractory Diabetic Macular Edema

Case Report Inherent Challenges in Managing Long Standing Refractory Diabetic Macular Edema Cronicon OPEN ACCESS EC OPHTHALMOLOGY Case Report Inherent Challenges in Managing Long Standing Refractory Diabetic Macular Edema V Swetha E Jeganathan 1,2 * and Karen Madill 3 1 Department of Ophthalmology,

More information

Diabetic Retinopathy Clinical Research Network

Diabetic Retinopathy Clinical Research Network Diabetic Retinopathy Clinical Research Network Peripheral Diabetic Retinopathy (DR) Lesions on Ultrawide-field Fundus Images and Risk of DR Worsening Over Time Version 4.0 July 21, 2017 peripheral dr lesions

More information

LCD L Bariatric Surgical Management of Morbid Obesity

LCD L Bariatric Surgical Management of Morbid Obesity LCD L32619 - Bariatric Surgical Management of Morbid Obesity Contractor Information Contractor Name: Novitas Solutions, Inc. Contractor Number(s): 04911, 07101, 07102, 07201, 07202, 07301, 07302, 04111,

More information

Course # Flashes and Floaters and Curtains, Oh My!

Course # Flashes and Floaters and Curtains, Oh My! Course # 132 Flashes and Floaters and Curtains, Oh My! FLASHES and FLOATERS and CURTAINS, OH MY!!! FLASHES OF LIGHT Vitreous is the villain Retinal traction Retinal hole Retinal tear Migraine Classic migraine

More information

Clinical Policy: Cochlear Implant Replacements Reference Number: CP.MP.14

Clinical Policy: Cochlear Implant Replacements Reference Number: CP.MP.14 Clinical Policy: Reference Number: CP.MP.14 Effective Date: 02/09 Last Review Date: 09/17 Revision Log Coding Implications See Important Reminder at the end of this policy for important regulatory and

More information

Physician s Compliance Guide

Physician s Compliance Guide Physician s Compliance Guide Updates to this guide will be posted on the Optum website and can be found at: http://www.optumcoding.com/product/updates/2013pcg/pcg13 Please use the following password to

More information